RXRX Q3 2024 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+158.2% YoY

Gross Profit

$14M53.7% margin

Operating Income

-$98M-377.1% margin

Net Income

-$96M-366.8% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+81.1%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$64M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$726M

Total Liabilities

$202M

Stockholders' Equity

$525M

Cash & Equivalents

$428M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$10M	+158.2%
Gross Profit	$14M	-$775,000	+1906.8%
Operating Income	-$98M	-$100M	+1.2%
Net Income	-$96M	-$93M	-2.9%

Revenue Segments

License and Service

$26M100%